Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.

ABSTRACT:

Background

Gliomas are the most common primary brain malignancy in adults, with treatment advances limited by challenges like the blood-brain barrier, tumour heterogeneity, and an immunosuppressive microenvironment. Tumour vaccines, such as adenoviral vector and mRNA-based vaccines, may overcome these barriers, but the ability of glioma patients to mount an immune response to these therapies remains unclear. This study assesses immune responses to adenoviral DNA and mRNA-based COVID-19 vaccinations in a glioma-enriched population as a model for glioma-based vaccine therapies.

Methods

COVID-19 naïve glioma and non-glioma solid tumour patients, along with healthy volunteers, were recruited between May 2021 and December 2022. Blood samples were collected at various time points:

SUBMITTER: Yuile A 

PROVIDER: S-EPMC12528327 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature